Is Seattle Genetics Stock a Buy?

Seattle Genetics (NASDAQ: SGEN) started last year with one product on the market -- Adcetris for Hodgkin lymphoma -- but it is quickly transforming into a multi-product oncology company. The U.S. Food and Drug Administration (FDA) approved a second drug, Padcev for locally advanced or metastatic urothelial cancer, in December, and days later, Seattle Genetics submitted breast cancer drug tucatinib for regulatory approval.

This week brought another reason for optimism: The company said the FDA accepted tucatinib for priority review and set an action date for Aug. 20.

Image source: Getty Images.

Continue reading

Source Fool.com